Detailed Information on Publication Record
2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study
KAYSER, S., R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO et. al.Basic information
Original name
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study
Authors
KAYSER, S. (guarantor), R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO, Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), E. H. ESTEY, C. M. SHAW, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Pavel ZAK (203 Czech Republic), M. R. BAER, A. M. BRUNNER, T. SZOTKOWSKI, Petr CETKOVSKY (203 Czech Republic), D. GRIMWADE, R. B. WALTER, A. K. BURNETT, A. D. HO, G. EHNINGER, C. MULLER-TIDOW, U. PLATZBECKER, C. THIEDE, C. ROLLIG, A. SCHULZ, G. WARSOW, B. BRORS, J. ESTEVE, N. H. RUSSELL, R. F. SCHLENK and M. J. LEVIS
Edition
British journal of haematology, England, Wiley-Blackwell, 2021, 0007-1048
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.615
RIV identification code
RIV/00216224:14110/21:00120102
Organization unit
Faculty of Medicine
UT WoS
000613871100001
Keywords in English
acute myeloid leukaemia; t(8;16)(p11;p13)/MYST3-CREBBP; whole-genome sequencing; allogeneic haematopoietic cell transplantation; outcome
Tags
International impact, Reviewed
Změněno: 7/6/2021 08:50, Mgr. Tereza Miškechová
Abstract
V originále
In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5 center dot 48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0 center dot 01) and those with complex karyotype (P = 0 center dot 04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0 center dot 04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
Links
NV15-25809A, research and development project |
|